Lv7
4310 积分 2023-06-12 加入
Mazdutide versus placebo in Chinese adults with type 2 diabetes
13天前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
13天前
已完结
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
28天前
已完结
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
28天前
已完结
Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Combination with Bolus Insulin in Individuals with Type 2 Diabetes on Basal-Bolus Regimens (ONWARDS 4)
1个月前
已关闭
Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Combination with Bolus Insulin in Individuals with Type 2 Diabetes on Basal-Bolus Regimens (ONWARDS 4)
1个月前
已关闭
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
1个月前
已完结
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
1个月前
已完结
胰高糖素样肽-1受体激动剂联合胰岛素治疗2型糖尿病专家共识（2025版）
1个月前
已完结
Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
2个月前
已完结
皖公网安备34019202002308
